What’s the impact of YNP initiatives? On this first part of the interview we talked to Dr Orsolya Cseprekál (outgoing chair). #era25 #beyondnephrology #ynp

What’s next for the YNP initiatives? This is the 2nd part of the interview we talked to Dr Safak Mirioglu (Chair elect). #era25 #beyondnephrology #ynp

#ERA25 #BeyondNephrology Symposium: Personalized approach in cardiometabolic kidney disease 📍 Resistance to novel kidney protective agents: a concept to be developed. 👤 Beatriz Fernandez Fernandez (Spain) Beatriz Fernandez Fernandez 🚨 Very nice presentation👏💯 highlighting ▶️ We still

First in Novel CKD Treatments Beyond the Pillars (room K), Jonathan Barratt presenting 🥁Changes in proteinuria and kidney function in subgroups of patients with IgAN defined by baseline Gd-IgA1 levels in a Phase 1/2 study of zigakibart Zigakibart= humanized MAb that blocks

Rainer Oberbauer presented genome-wide non-HLA and HLA alloimmunity at #ERA25. ~50% of graft loss results from alloimmune reactions, such as rejections. Combining eplet scores (Eplet MM and PIRCHE) may aid in predicting de novo DSA formation. However, eplet scores are not

Tobias B. Huber International Society of Glomerular Disease #ERA25 Insights on Anti-Nephrin 🧬 🔹 Diagnostic aid — may even help avoid biopsy in select cases! 🔹 Guides treatment — aligns with immunosuppressive responsiveness 🔹 Potential role in prognostication — under investigation Exciting future for precision nephrology! Tweets by

⏩ Next in Novel CKD Treatments Beyond the Pillars #ERA25 📌 Win Ratio Analysis of the Cardiovascular Safety of Vadadustat in Patients With CKD-Related Anemia Undergoing Dialysis 🎙️Presented by Glenn Chertow 💊Vadadustat (VADA)= an oral HIF-PHI, stimulates endogenous EPO and red

❗️Check out the latest breakthroughs in Nephrology from the past year: 💥 CKD: Finerenone and SGLT2 inhibitors are leading the way! 💥 Glomerulonephritis: A wave of innovative therapies for IgA Nephropathy! 💥 Dialysis: Updates on volume management, cannulation techniques, and

🔥🔥🔥 the 2nd late breaking clinical trial session 🔥🔥🔥 ▶️ 1st up: Vlado Perkovic presenting Sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study If anyone is already interested a phase 2 study has

An interesting interview to Prof Wolfgang Winkelmayer, Baylor College of Medicine About A phase 2b trial of efficacy and safety of factor XI inhibition with MK-2060 for preventing arteriovenous graft thrombosis in haemodialysis patients 👇. Here the highlights. #ERA25

🔬 Insightful talk by Valentina Raglianti on the role of anti-slit diaphragm antibodies in MCD & FSGS — paving the way for future diagnostic breakthroughs! #ERA25 #NephTwitter #GlomerularDisease

#ERA25 ⏳ Long-term data on Imlifidase 👇👇👇 Does it confirm durability and safety for wider clinical use? #Transplant #NephTwitter #Desensitisation Tweets by Arunkumar

Treatment options for post-tx recurrent FSGS - Evolving! 👇👇 #ERA25

#ERA25 HLA-incompatible desensitisation: ✅ Present options: plasmapheresis, IVIG, rituximab 🆕 Emerging therapies: obinutuzumab, ofatumumab, anti-CD38 combos 🚀 Cutting-edge in trials: Imlifidase, CAR-T, Daratumumab + Belatacept (ATTAIN study) Future is promising! 👇👇

📌 Anti-CD38 in AMR – Key Takeaways from #ERA25 🔹 Significant reduction in MVI 🔹 Depletes antibody-secreting cells, but variable effect on DSA MFI 🔹 May help in desensitization: responders vs non-responders 🔹 Effect is transient—risk of rebound, role for combo therapies? 🔹

Results of the SWEETSTONE TRIAL 🔥at #ERA25 #BeyondNephrology by Dr. Manuel Anderegg Manuel Anderegg 🎯iSGLT2 ⬆️ urinary citrate! ❓Does this mean we can we treat stone formers with iSGLT2❓ 👉🏻The EMPASTONE trial will bring us the answer!

Anti-CD38 therapy in AMR #ERA25 ✔️ ↓ MVI (via NK cell depletion) ✔️ Depletes plasma cells; DSA impact variable ✔️ Role in desensitisation (responders vs non-responders) ⚠️ Transient effect, possible rebound ✅ Safe, ~10% TCMR seen #cAMR #Transplant #NephTwitter

Thank you very much #ERA25 for everything I have learned in these few days. High human and scientific quality. And a special mention to the SOME team. A pleasure to work with you! #beyondnephrology ERA - European Renal Association

Meet & Greet was a success! Thanks to all participants! 🎉 #ERA25 ERA - European Renal Association

Antibody-mediated rejection—treatment standard 🧐Finally, there is hope for effective, approved therapies targeting different aspects of AMR pathobiology ▶️academic.oup.com/ndt/article/40…